Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in the Italian Clinical Practice: a Retrospective Cohort, Observational Study
This study is completed in Italy. It focuses on Schizophrenia.
SchizophreniaObservationalOver 18 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This observational study follows adults living with schizophrenia to understand their experience, outcomes, or changes over time.
What would participation involve?
Participants may answer questionnaires, join interviews, or provide follow-up information, attend study visits with the research team. The registry lists locations in Italy.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: December 2016
Recruitment status
Completed
Enrollment listed in the registry
262
Sponsor
Otsuka Pharmaceutical Europe Ltd
Sponsor type
Pharmaceutical company
Study type
Observational
Intervention type
Interview / survey / observational
Study phase
Not clearly listed
Locations
Italy
Age range
Over 18 Years
Official registry ID
NCT03005769
Official title
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in the Italian Clinical Practice: a Retrospective Cohort, Observational Study
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT03005769. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Italy · 20 sites
Centro Salute Mentale
Ancona
Site status: Not listed — confirm with the team
SPDC ASST Spedali Civili
Brescia
Site status: Not listed — confirm with the team
Azienda Ospedaliero-Universitaria di Cagliari
Cagliari
Site status: Not listed — confirm with the team
Policlinico "G. Rodolico"
Catania
Site status: Not listed — confirm with the team
Policlinico Mater Domini
Catanzaro
Site status: Not listed — confirm with the team
Azienda Ospedaliero-Universitaria Careggi
Florence
Site status: Not listed — confirm with the team
Casa Di Cura Neuropsichiatrica Villa Von Siebenthal
Genzano di Roma
Site status: Not listed — confirm with the team
Ospedale Maria S.S. dello splendore
Giulianova
Site status: Not listed — confirm with the team
ASL Lecce
Lecce
Site status: Not listed — confirm with the team
ASST Grande Ospedale Metropolitano
Milan
Site status: Not listed — confirm with the team
Azienda Ospedaliera Fatebenefratelli e Oftalmico
Milan
Site status: Not listed — confirm with the team
Ospedale San Gerardo
Monza
Site status: Not listed — confirm with the team
SCDU Psichiatria. AOU San Luigi Gonzaga
Orbassano
Site status: Not listed — confirm with the team
Azienda Ospedaliera di Padova
Padova
Site status: Not listed — confirm with the team
Clinica Psichiatrica. Università di Palermo
Palermo
Site status: Not listed — confirm with the team
Università degli Studi di Perugia
Perugia
Site status: Not listed — confirm with the team
Centro di Salute Mentale
Pomezia
Site status: Not listed — confirm with the team
ASL Salerno
Pontecagnano
Site status: Not listed — confirm with the team
Azienda Ospedaliera Universitaria Senese
Siena
Site status: Not listed — confirm with the team
Azienda ULSS 9 Treviso
Treviso
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Is this an interview, survey, or observational study?
This appears to be a interview / survey / observational study. Phase is mainly useful to check for medication studies and some device studies.
Who might this study be for?
This study may concern people with schizophrenia; age range: Over 18 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to answer questionnaires or take part in interviews. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Could the questions feel emotionally difficult or personal?
If the study involves interviews or questionnaires, some questions may feel personal or emotionally sensitive. Ask whether you can skip questions, pause, stop, and how your answers will be protected. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Otsuka Pharmaceutical Europe Ltd, which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This study is completed. It focuses on schizophrenia and currently lists study information in Argentina, Brazil, Canada, France, Germany, Italy, Spain, and the United Kingdom.